A preliminary study for constructing a bioartificial liver device with induced pluripotent stem cell-derived...

Area of Science:

• Biomedical Engineering
• Tissue Engineering
• Regenerative Medicine

Background:

• Bioartificial liver systems aim to support patients with liver failure using bioreactors and hepatocytes.
• Immunological rejection of hepatocytes is a major challenge, limiting device performance.
• Patient-derived induced pluripotent stem (iPS) cells offer a solution to immunological rejection in bioartificial liver systems.

Purpose of the Study:

• To evaluate the feasibility of a bioartificial liver system utilizing iPS cell-derived hepatocyte-like cells.
• To assess the differentiation potential and functionality of iPS cells into hepatocyte-like cells for liver support.

Main Methods:

• Mouse iPS cells were differentiated into hepatocyte-like cells through embryoid bodies and definitive endoderm.
• Differentiation was confirmed via morphology, PCR, and functional assays.
• iPS cell-derived hepatocytes were cultured in a 0.2 μm pore bioreactor for 7 days, with albumin secretion measured by ELISA.

Main Results:

• Differentiated iPS cells exhibited hepatocyte morphology, including glycogen deposition and microvilli.
• Increased albumin mRNA expression and functional albumin and urea production were observed.
• Albumin accumulated in the bioreactor medium over 7 days, indicating sustained function.

Conclusions:

• Combining a 0.2-μm pore bioreactor with iPS cell-derived hepatocytes is a promising strategy for bioartificial liver systems.
• This study provides foundational data for developing iPS cell-based bioartificial liver technologies.
• The approach addresses immunological rejection, paving the way for improved liver support devices.